OBJECTIVES: In 2018’s ADA/EASD recommendations, intensified insulin regimens, either by switching to premixed insulins or adding injections of prandial insulin, are considered final approach to glycemic management for patients with type 2 diabetes (T2D) insufficiently controlled under basal insulin. This study evaluated cost savings associated with Premix versus Basal-Bolus regimen when intensifying insulin therapy in Algeria. METHODS: Clinical data including daily insulin dose, number of injections, and average HbA1c were obtained from BAROMETER RWE nationwide study performed in Algeria (N=14.609 T2D patients enrolled). Drug costs were taken from IQVIA February 2019 (only insulin analogs were considered). Costs of a new needle, lancet and blood glucose test strip were also included. In the absence of data from BAROMETER RWE study, it was assumed in the base case that patients would check their blood glucose before each insulin injection. Sensitivity analyses were performed under different insulin analogs brands, different doses (within interquartile range), different number of injections (one more for Premix and one less for Basal-Bolus), by assuming patients test their blood glucose only once daily, and use a needle twice before replacing it. RESULTS: The annual drug cost for insulin per patient on Premix regimen was 39,7% lower than for Basal-Bolus at 74.444 DZD and 123.400 DZD respectively. The annual cost of needles, lancets and test strips was 50% lower with Premix at 44.430 DZD compared with 88.830 DZD for Basal-Bolus group. Overall, the total annual cost per patient, excluding oral medications, was 44% lower in Premix group than with Basal-Bolus (118.874 DZD versus 212.230 DZD respectively), and 66,4% lower when considering extra-cost of intensification from basal insulin regimen. Comparable savings were demonstrated for all scenarios included in the sensitivity analyses (range from -37.897 to -107.967 DZD). CONCLUSIONS: For equivalent efficacy, Premix intensified insulin regimen was cost-saving compared to Basal-Bolus from payers perspective in Algeria.